A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2-arm study to investigate the safety and immunogenicity of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers

Project Details

StatusActive
Effective start/end date2/09/2431/05/27

Funding

  • Sanofi-Aventis: A$398,010.00